Amarin says continues to see Vascepa launch early in 1Q13 Amarin previously guided that it would make a decision to hire prospective sales representatives as part of its continued Vascepa commercialization preparations before the end of November. Amarin now expects to make this decision in the first half of December and continues to anticipate the launch of Vascepa early in 1Q13.
Amarin surges after court sides with company on Vascepa exclusivity Shares of Amarin Pharmaceuticals are surging higher after a U.S. district court sided with the company in its challenge of the Food and Drug Administrationís determination that Amarinís new drug, Vascepa, is not entitled to a five-year period of market exclusivity under the Federal Food, Drug, and Cosmetic Act. The court granted the company's motion for summary judgment and the decision denying Amarinís claim for exclusivity was vacated. The matter was remanded to the FDA for proceedings consistent with the court's opinion. In afternoon trading, Amarin shares jumped as high as $2.80 and are now up 22.5% to $2.39.